Skip to main content
. 2015 Oct;100(10):1334–1339. doi: 10.3324/haematol.2015.125864

Figure 5.

Figure 5.

PFS (A) and OS (B) by depth of response measured by degree of M-protein level reduction for patients assigned to POM + LoDEX. LoDEX: low-dose dexamethasone; OS: overall survival; PFS: progression-free survival; POM: pomalidomide.